Scheid; Johannes

Patent Applications and Registrations

Patent applications and USPTO patent grants for Scheid; Johannes.The latest application filed is for "broadly neutralizing anti-hiv antibodies and epitope therefor".

Company Profile

2.11.11

Scheid; Johannes - New York NY

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor App 20220002391 - Nussenzweig; Michel ; et al.	2022-01-06
Nucleic acids encoding broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 ENV subunits Grant 11,155,605 - Nussenzweig , et al. October 26, 2	2021-10-26
Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use Thereof App 20210230254 - Scheid; Johannes ; et al.	2021-07-29
Human immunodeficiency virus neutralizing antibodies and methods of use thereof Grant 10,889,633 - Scheid , et al. January 12, 2	2021-01-12
Highly Active Agonistic Cd4 Binding Site Anti-hiv Antibodies (haads) Comprising Modified Cdrh2 Regions That Improve Contact With App 20200165325 - Diskin; Ron ; et al.	2020-05-28
Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor App 20200140528 - Nussenzweig; Michel ; et al.	2020-05-07
Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with gp120 Grant 10,590,187 - Diskin , et al.	2020-03-17
Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits Grant 10,421,803 - Nussenzweig , et al. Sept	2019-09-24
Highly Active Agonistic Cd4 Binding Site Anti-hiv Antibodies (haads) Comprising Modified Cdrh2 Regions That Improve Contact With Gp120 App 20180237506 - Diskin; Ron ; et al.	2018-08-23
Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor App 20180171001 - Nussenzweig; Michel ; et al.	2018-06-21
Human Immunodeficiency Virus Neutralizing Antibodies and Methods of Use Thereof App 20180079800 - Scheid; Johannes ; et al.	2018-03-22
Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120 Grant 9,890,207 - Diskin , et al. February 13, 2	2018-02-13
Human immunodeficiency virus neutralizing antibodies and methods of use thereof Grant 9,783,594 - Scheid , et al. October 10, 2	2017-10-10
Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth Grant 9,493,549 - Diskin , et al. November 15, 2	2016-11-15
Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use Thereof App 20140328862 - Scheid; Johannes ; et al.	2014-11-06
HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120 Grant 8,673,307 - Nussenzweig , et al. March 18, 2	2014-03-18
Anti-hiv Antibodies Having Increased Potency And Breadth App 20130209454 - Diskin; Ron ; et al.	2013-08-15
Compositions And Methods For Improving Potency And Breadth Of Hiv Antibodies App 20120288502 - Diskin; Ron ; et al.	2012-11-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.